CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.
“We are extremely encouraged by the breadth of clinical data enabled by Foundation Medicine’s platform being presented at this year’s AACR annual meeting,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “These data elucidate the benefits and value of integrating clinically relevant and highly reliable molecular information into oncologic clinical practice. Cancer is a complex disease to treat and manage, and Foundation Medicine’s singular comprehensive genomic profiling approach arms physicians with the right information to enable informed, outcomes-oriented treatment decisions for patients.”
The company's molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the genomic alterations in a patient's cancer. The data to be presented at AACR add to a growing body of evidence revealing the critical distinctions between hotspot-based testing, which analyses a single or small set of genes or a specific region in such genes, and validated comprehensive genomic profiles, which analyze the entire coding regions of cancer genes and detect all four classes of genomic alterations.
The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:
Date & Time: Sunday, April 19, 2015 from 3:20 to 3:35 p.m. ET
Title:
Co-occurring genomic alterations define major subsets of KRAS-mutant
lung adenocarcinoma (LUAC) with distinct biology and therapeutic
vulnerabilities
Abstract: 968
Session: Proffered
Papers: Oncogenic Signaling and Cell Death
Location: Room
121
Presenter: Ferdinandos Skoulidis, M.D., Ph.D.,
University of Texas MD Anderson Cancer Center
Collaborators: University
of Texas MD Anderson Cancer Center, University of Texas
Southwestern Medical Center, Wexner Medical Center, The Ohio State
University, College of Medicine – Seoul National University, Yale Cancer
Center, Dana Farber Cancer Institute
Date & Time: Tuesday, April 21, 2015 from 3:20 to 3:35 p.m. ET
Title:
The complex genomic landscape of glial tumors reveals distinct
subclasses and potential therapeutic targets associated with clinical
responses to targeted inhibitors
Abstract: 4667
Session:
Precision Medicine in the Clinic
Location: Terrace
Ballroom IV (400 Level)
Presenter: Juliann Chmielecki,
Ph.D., associate director, cancer genomics, Foundation Medicine
Collaborator:
University of California, San Diego
Date & Time: Tuesday,
April 21, 2015 from 4:05 to 4:20 p.m. ET
Title: A novel
companion diagnostic predicts response to the PARP inhibitor rucaparib
in ovarian cancer
Abstract: 4670
Session: Precision
Medicine in the Clinic
Location: Terrace Ballroom IV (400
Level)
Presenter: James Sun, Ph.D., manager, biomarker
development and analysis, Foundation Medicine
Collaborators:
Institute of Cancer Sciences, University of Texas MD Anderson Cancer
Center, Princess Margaret Cancer Center, Walter and Eliza Hall Institute
of Medical Research, The Ohio State University, Clovis Oncology,
University of Washington School of Medicine
The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:
Date & Time: Sunday, April 19, 2015 from 1:00 to 5:00 p.m. ET
Title:
Understanding oncogenic fusions: lessons learned from inflammatory
myofibroblastic tumor
Abstract: 497
Session: Pediatric
Cancer: Basic Science 1
Poster Board: 23
Locations: Section
20
Presenter: Merida Childress, Vanderbilt University
Collaborator:
Vanderbilt University School of Medicine, University of
Toronto, Brigham and Women’s Hospital
Date & Time: Sunday, April 19, 2015 from 1:00 to 5:00 p.m. ET
Title:
Exploratory analyses suggest ovarian tumors with somatic or germline
loss of function mutations in BRCA1 or BRCA2 are biologically
similar and sensitive to PARP inhibition
Abstract: 611
Session:
Tumor- and Blood-based Genotyping
Poster Board: 9
Locations:
Section 26
Presenter: Brian Dougherty, Ph.D., AstraZeneca
Collaborator:
AstraZeneca, University College London Center Institute
Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00
p.m. ET
Title: Activation of MET via diverse exon 14
skipping mutation occurs in multiple tumor types and confers clinical
sensitivity to MET inhibitors
Abstract: 1118
Session:
Functional Genomics
Poster Board: 20
Locations: Section
5
Presenter: Garrett M. Frampton, Ph.D., senior
bioinformatics scientist, Foundation Medicine
Date & Time: Monday,
April 20, 2015 from 8:00 a.m. to 12:00 p.m. ET
Title: Development
and validation of an NGS-based assay to detect all classes of genomic
alterations in circulating tumor cells (CTCs) from patients with solid
tumors
Abstract: 1602
Session: Circulating Tumor
Cells
Poster Board: 23
Locations: Section 23
Presenter:
Allison Welsh, Ph.D., senior scientist, molecular biology &
sequencing, Foundation Medicine
Collaborator: University of
Wisconsin
Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00
p.m. ET
Title: Development of a clinical cell-free DNA assay
for cancer molecular profiling
Abstract: 2415
Session:
Circulating Free DNA 1
Poster Board: 18
Locations:
Section 21
Presenter: Travis Clark, Ph.D., senior
scientist, molecular biology & sequencing, Foundation Medicine
Date & Time: Tuesday, April 21, 2015 from 8:00 a.m. to 12:00
p.m. ET
Title: Rictor alterations elicit non-canonical
signaling mechanisms contributing to tumorigenicity and therapeutic
resistance in non-small cell lung cancer (NSCLC)
Abstract: 3576
Session:
Molecular Targets
Poster Board: 28
Locations: Section
30
Presenter: Dennis Ruder, University of Texas MD Anderson
Cancer Center
Collaborators: University of Texas MD Anderson
Cancer Center, University of Texas Southwestern Medical Center, Yale
Comprehensive Cancer Center
Date & Time: Tuesday, April 21, 2015 from 1:00 to 5:00 p.m. ET
Title:
Defects in DNA repair genes and sensitivity to cisplatin based
neoadjuvant chemotherapy (NAC) for bladder cancer
Abstract: 4298
Session:
Predictive BioMakers 2
Poster Board: 1
Locations:
Section 25
Presenter: Elizabeth R. Plimack, M.D., Fox
Chase Cancer Center
Collaborators: Fox Chase Cancer Center,
Thomas Jefferson University Hospital
Date & Time: Wednesday, April 22, 2015 from 8:00 a.m. to
12:00 p.m. ET
Title: Next generation sequencing enables new
approach to molecular cytogenetics
Abstract: 4927
Session:
New Technologies to Identify Genetic Alterations
Poster
Board: 23
Locations: Section 7
Presenter: Jie
He, Ph.D., senior manager, computational biology analysis, Foundation
Medicine
Date & Time: Wednesday, April 22, 2015 from 8:00 a.m. to
12:00 p.m. ET
Title: Comprehensive profiling of
immunoglobulin sequences using hybrid capture-based next generation
sequencing in B-cell hematologic malignancies
Abstract: 4737
Session:
Advances in Genomics and Transcriptomics
Poster Board: 3
Locations:
Section 1
Presenter: Michelle K. Nahas, Ph.D., senior
scientist, molecular biology & sequencing, Foundation Medicine
Collaborator:
Memorial Sloan-Kettering Cancer Center
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of molecular information and Foundation Medicine’s comprehensive genomic profiling to improve treatment decisions for patients. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that Foundation Medicine's comprehensive genomic profiling will not be able to identify genomic alterations in the same manner as prior clinical data, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.